BioSpace News Archive

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Monday, May 16, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended March 31, 2022 and provide a corporate update.

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported first quarter 2022 financial results.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report first quarter 2022 financial results on Monday, May 16, 2022.

Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company is scheduled to attend the BofA Securities 2022 Healthcare Conference.

Finch Therapeutics Group, Inc. today announced it will host a conference call and live webcast on Monday, May 16, 2022 at 8:00am ET to discuss updates to its development programs and other business highlights.

Oxurion NV announces top-line results from Part A of its Phase 2 trial of THR-687, an integrin antagonist, for the treatment of diabetic macular edema.

MannKind Corporation announced that it will be participating at upcoming conferences.

Immuron Limited is pleased to provide shareholders and the market with a progress update on the planned clinical trial to evaluate the efficacy of Travelan® and two third party non-antibiotic products in Travelers’ Diarrhea

Science 37 Holdings, Inc., the Agile Clinical Trial Operating System™, reported its financial results for the quarter ended March 31, 2022.

BioNTech SE reported financial results for the three months ended March 31, 2022 and provided an update on its corporate progress.